ArQule, Inc. (Nasdaq: ARQL) today announced that eight presentations of clinical and pre-clinical data on three early clinical-stage product candidates will take place during the 26th EORTC-NCI-AACR Symposium to be held November 18-21, 2014 in Barcelona, Spain.
These product candidates include: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family; and ARQ 761, a Beta lapachone analog being investigated as a promoter of NQ01-mediated programmed cancer cell necrosis.
Help employers find you! Check out all the jobs and post your resume.
